» Articles » PMID: 11400233

Surgical Treatment of Recurrent Pleomorphic Adenoma of the Parotid Gland: a Clinical Analysis of 52 Patients

Overview
Journal Head Neck
Date 2001 Jun 16
PMID 11400233
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Surgical management of recurrent pleomorphic adenoma of the parotid gland has a considerable risk of facial nerve injury and a high re-recurrence rate. To obtain more insight into this issue we evaluated our experiences.

Methods: Medical records and histologic material of all these patients (31 women and 21 men), who had been treated from 1976-1995 were reviewed. Median interval between initial treatment and commencement of recurrences was 3 (0.8-18) years. Last surgery consisted of parotidectomy in 48 patients (92%), including 19 (40%) total procedures and wide local excision with involved skin in four patients.

Results: At a median follow-up of 9 years, eight patients (8/52; 15%) had re-recurrences develop, including 4 of 21 patients (19%) after a previous parotidectomy (group I) and 4 of 31 patients (13%) without prior parotidectomy (group II). The chance of re-recurrence in a group of patients with a minimal follow-up of 10 years after salvage surgery was 17% (4 of 24). The risk of a new relapse was, respectively, 4% and 8% at 1 and 5 years after treatment of recurrent disease. Acceptable N.VII function was preserved in 45 of the 49 (92%) nerves at risk. The risk of N.VII injuy was higher and more serious in group I (29% vs 10% in group II). The function of four of the five (80%) reconstructed zygomaticotemporal branches of the N.VII was adequate.

Conclusion: Surgical treatment of recurrent pleomorphic adenoma of the parotid gland, usually consisting of a parotidectomy with wide extent and eventually facial nerve reconstruction, demonstrates favorable results with acceptable morbidity. The risk of new relapse and N.VII injury was higher after previous parotidectomy.

Citing Articles

"Unraveling the Tapestry": A Retrospective Exploration of Recurrent Parotid Pleomorphic Adenoma Cases.

Sundarajan K, Subagar A, Arumugam K Indian J Otolaryngol Head Neck Surg. 2024; 76(4):3227-3233.

PMID: 39130327 PMC: 11306486. DOI: 10.1007/s12070-024-04650-7.


Novel Detection of Pleomorphic Adenomas via Analysis of Ga-DOTATOC PET/CT Imaging.

Johnson F, Kloppenburg M, Hofauer B, Wollenberg B, Hoch C, Stogbauer F Cancers (Basel). 2024; 16(15).

PMID: 39123352 PMC: 11311107. DOI: 10.3390/cancers16152624.


Novel Discovery of the Somatostatin Receptor (SSTR2) in Pleomorphic Adenomas via Immunohistochemical Analysis of Tumors of the Salivary Glands.

Johnson F, Hofauer B, Wirth M, Wollenberg B, Stogbauer F, Notohamiprodjo S Cancers (Basel). 2023; 15(15).

PMID: 37568733 PMC: 10417029. DOI: 10.3390/cancers15153917.


Effect of chitosan combined with hyaluronate on promoting the recovery of postoperative facial nerve regeneration and function in rabbits.

Liu H, Huang H, Bi W, Tan X, Li R, Wen W Exp Ther Med. 2018; 16(2):739-745.

PMID: 30116328 PMC: 6090212. DOI: 10.3892/etm.2018.6238.


Pleomorphic adenoma of the vulva, clinical reminder of a rare occurrence.

Su A, Apple S, Moatamed N Rare Tumors. 2012; 4(1):e16.

PMID: 22532914 PMC: 3325743. DOI: 10.4081/rt.2012.e16.